Abortion providers and advocates are making plans for future disruptions to reproductive care after the US supreme court temporarily continued nationwide access to mail-order mifepristone on Thursday while several legal challenges wind their way through the lower courts.
Three lawsuits, including a suit brought by Louisiana against the US Food and Drug Administration (FDA), seek to limit access to mifepristone, one of two abortion medications. Limitations on abortion medication could have significant ripple effects throughout the pharmaceutical industry, allowing a single state to regulate medications for the entire country.
